Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes

Israel Medical Association Journal

Volumn 6, Issue 5, 2004, Pages 271-275

  Weintrob, Naomi ^a,b   Shalitin, Shlomit ^a,b   Phillip, Moshe ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adolescents; Children; Continuous subcutaneous insulin infusion; Diabetes; Multiple daily insulin injections; Pumps

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; BLOOD GLUCOSE MONITORING; CHILD; COST BENEFIT ANALYSIS; DIABETIC KETOACIDOSIS; DISEASE CONTROL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION RISK; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INTERMETHOD COMPARISON; PATIENT SATISFACTION; PATIENT SELECTION; PHYSICAL ACTIVITY; REVIEW;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; PATIENT SATISFACTION;

EID: 2442431708     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.
2. Weissberg-Benchall J, Glasgow AM, Tynan WD, Wirtz P, Turck J, Ward J. Adolescent diabetes management and mismanagement. Diabetes Care 1995;18:77-83.
3. Wing RR, Nowalk MP, Marcus MD, Koeske R, Finegold D. Subclinical eating disorders and glycemic control in adolescens with type 1 diabetes. Diabetes Care 1986;9:162-7.
4. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes, mellitus: Diabetes Control and Complications Trial. J Pediatrics 1994;125:177-88.
5. Kostraba JN, Dorman JS, Orchard TJ, et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 1989; 12-686-93.
6. Shalitin S, Josefsberg Z, Lilos P, De-Vries L, Phillip M, Weintrob N. Bedside scoring procedure for the diagnosis of diabetic peripheral neuropathy in young patients with type 1 diabetes. J Pediatr Endocrinol Metab 2002;15:613-20.
7. Hepp KD, Renner R, Funcke HJ, Mehnert H, Haerten R, Kresse H. Glucose homeostasis under continuous intravenous insulin therapy in diabetics. Horm Metab Res 1966;7(Suppl):72-6.
8. Genuth S, Martin P. Control of hyperglycemia in adult diabetics by pulsed insulin delivery. Diabetes 1977;26:571-81.
9. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br Med J 1978;i:204-7.
10. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979;300:573-8.
11. Koivisto VA, Yki-Jarvinen H, Helve E, Karonen SL, Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986;3578-82.
12. Edge JA, Matthews DR, Dunger DB. The dawn Phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf) 1990;33:729-37.
13. Lauritzen T. Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabeteologia 1983;24:326-9.
14. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. The Study Group for the Development of Pump Therapy in Diabetes. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetes patients on intensified treatment. Diabetes Care 2000;23:1232-5.
15. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999;22:784-8.
16. Kaufman FR, Halvorson M, Fisher L, Pitukcheewanont P. Insulin pump therapy in type 1 pediatric patients. J Pediatr Endocrinol Metab 1999;12(Suppl 3):759-64.
17. Schiffrin A, Desrosiers M. Moffatt M, Belmonte MM. Feasibility of strict diabetes control in insulin-dependent diabetic adolescents. J Pediatr 1983;103:522-7.
18. Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989;32:421-6.
19. Pietri A, Raskin P. Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy. Diabetes Care 1981:4:624-6.
20. Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003;112:559-64.
21. Colquitt J. Roile P, Waugh N. Are analogue insulins better than soluble in continous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-6.
22. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002;25:439-44.
23. Cohen D, Weintrob N, Benzaquen H, Galatzer A, Fayman G, Phillip M. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in adolescents with type 1 diabetes; a randomized open crossover trial. J Pediatr Endocrinol Metab 2003;16:1047-50.
24. Conrad SC, McGrath MT, Gitelman SE. Transition from multiple daily injections to continuous subcuteneous insulin infusion in type 1 diabetes mellitus. J Pediatr 2002;140:235-40.
25. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br Med J 2002:324:1-6.
26. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079-87.
27. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;161:2293-300.
28. Tamborlane WV, Sherwin RS, Genel M, Felig P. Outpatient treatment of juvenile-onset diabetes with a preprogrammed portable subcutaneous insulin infusion system. Am J Med 1980;68:190-6.
29. Saha ME, Huuppone T, Mikael K, Juuti M, Komulainen J. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:1005-10.
30. Schiffrin A, Belmonte MM. Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one-year prospective study. Diabetes 1982;21:255-64.
31. Boland EA, Grey M. Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-84.
32. Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 2000;23:579-82.
33. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001;107:351-6.
34. Raile K, Noelle V, Landgraf R, Schwarz HP. Weight in adolescents with type 1 diabetes mellitus during continuous subcutaneous insulin infusion (CSII) therapy. J Pediatr Endocrinol Metal 2002;15:607-12.
35. Weintrob N, Schechter A, Benzaquen H, et al. Glycemic patterns detected by continuous subcutaneous glucose sensing in children with type 1 diabetes treated by MDI or CSII [Abstract]. Diabetes 2003;52(Suppl 1):430.
36. Lepore M, Pampenelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
37. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003;26:1321-2.
38. Boland E, Weinzimer S, Ahern JA, Steffen A, Tamborlane W. Randomised prospective trial of CSII vs MDI with glargine in children: a preliminary report [Abstract]. Diabetes 2003;52(Suppl 1):92.
39. Weinzimer S, Ahern J. Boland E, Steffen A, Tamborlane W. Continuous subcutaneous insulin infusion (CSII) is safe and effective in very young children with type 1 diabetes (TIDM) [Abstract]. Diabetes 2002;51(Suppl 2):1744.
40. Renard E, Shah R, Miller M, Kolopp M, Costalat G, Bringer J. Sustained safety and accurary of central IV glucose sensors connected to implanted insulin pumps and short-term closed-loop trials in diabetic patients [Abstract]. Diabetes 2003;52(Suppl 2):155.